Related Experiment Video
Updated: May 3, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
Otávio Clark1, Tobias Engel Ayer Botrel1, Luciano Paladini1
1Evidências Consulting, Campinas, Brazil.
Objective:
To perform a systematic review and meta-analysis of randomized controlled trials that compared the efficacy of targeted therapy to conventional chemotherapy (CT) in patients with metastatic triple-negative breast cancer (TNBC).
Methods:
Several databases were searched, including Medline, Embase, LILACS, and CENTRAL. The primary end point was progression-free survival (PFS). We performed a meta-analysis of the published data. The results are expressed as hazard ratio (HR) or risk ratio, with their corresponding 95% confidence intervals (95% CIs).
Results:
The final analysis included twelve trials comprising 2,054 patients with TNBC, which compared conventional CT alone against CT combined with targeted therapy (bevacizumab [Bev], sorafenib [Sor], cetuximab, lapatinib, and iniparib). PFS was superior in previously untreated patients with TNBC who received Bev plus CT compared to CT alone (fixed effect, HR 0.62, 95% CI 0.51-0.75; P<0.00001). Also, PFS was higher in one study that tested Bev plus CT combination in previously treated patients (HR 0.49, 95% CI 0.33-0.74; P=0.0006). Sor plus CT was also tested as first-line and second-line treatments. The pooled data of PFS favored the combination CT plus Sor (fixed effect, HR 0.69, 95% CI 0.49-0.98; P=0.04). Comparisons of iniparib plus CT also had a better PFS than CT alone (fixed effect, HR 0.75, 95% CI 0.62-0.90; P=0.002).
Conclusion:
Targeted therapy, when associated with conventional CT, demonstrated gains in the PFS of patients with TNBC.
Insights
Targeted therapy combined with chemotherapy improves progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC). This meta-analysis confirms targeted therapy
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Metastatic triple-negative breast cancer (TNBC) presents a significant clinical challenge.
- Conventional chemotherapy (CT) is a standard treatment, but efficacy can be limited.
- Novel therapeutic strategies are needed to improve outcomes for TNBC patients.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs).
- To compare the efficacy of targeted therapy plus CT versus CT alone in metastatic TNBC.
- To evaluate the impact on progression-free survival (PFS).
Main Methods:
- Systematic search of multiple databases (Medline, Embase, LILACS, CENTRAL).
- Inclusion of twelve RCTs with 2,054 TNBC patients.
- Meta-analysis of PFS using hazard ratios (HR) and 95% confidence intervals (CIs).
Main Results:
- Bevacizumab (Bev) plus CT significantly improved PFS in previously untreated TNBC (HR 0.62).
- Bev plus CT also showed improved PFS in previously treated patients (HR 0.49).
- Sorafenib (Sor) plus CT and iniparib plus CT demonstrated superior PFS compared to CT alone.
Conclusions:
- Targeted therapy, when combined with conventional CT, offers significant benefits in PFS for TNBC patients.
- Bevacizumab and sorafenib show particular promise in improving outcomes.
- These findings support the integration of targeted therapies into TNBC treatment regimens.
More Related Videos
10:01Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies